Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

61 Downloads (Pure)

Resumé

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

OriginalsprogEngelsk
Artikelnummer1701190
TidsskriftEuropean Respiratory Journal
Vol/bind52
Udgave nummer2
Antal sider14
ISSN0903-1936
DOI
StatusUdgivet - aug. 2018

Fingeraftryk

Pseudomonas aeruginosa
Cross-Sectional Studies
Lung Diseases
Pseudomonas Infections
Microbial Drug Resistance
Chronic Obstructive Pulmonary Disease
Logistic Models
Regression Analysis
Delivery of Health Care

Bibliografisk note

The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2018.

Citer dette

@article{bd3f22243f4a4a108436dbe85241848d,
title = "Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients",
abstract = "Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2{\%} and 2.0{\%}, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67{\%}. In contrast, the rate of P. aeruginosa-CAP was 2{\%} in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.",
keywords = "Pneumonia, Admission, Infectious diseases",
author = "Restrepo, {Marcos I} and Babu, {Bettina L} and Reyes, {Luis F} and Chalmers, {James D} and Soni, {Nilam J} and Oriol Sibila and Paola Faverio and Catia Cilloniz and William Rodriguez-Cintron and Stefano Aliberti and {Heitmann B{\o}dtger}, {Uffe Christian} and GLIMP",
note = "The content of this work is not subject to copyright. Design and branding are copyright {\circledC}ERS 2018.",
year = "2018",
month = "8",
doi = "10.1183/13993003.01190-2017",
language = "English",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia

T2 - a multinational point prevalence study of hospitalised patients

AU - Restrepo, Marcos I

AU - Babu, Bettina L

AU - Reyes, Luis F

AU - Chalmers, James D

AU - Soni, Nilam J

AU - Sibila, Oriol

AU - Faverio, Paola

AU - Cilloniz, Catia

AU - Rodriguez-Cintron, William

AU - Aliberti, Stefano

AU - Heitmann Bødtger, Uffe Christian

AU - GLIMP

N1 - The content of this work is not subject to copyright. Design and branding are copyright ©ERS 2018.

PY - 2018/8

Y1 - 2018/8

N2 - Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

AB - Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

KW - Pneumonia

KW - Admission

KW - Infectious diseases

U2 - 10.1183/13993003.01190-2017

DO - 10.1183/13993003.01190-2017

M3 - Journal article

C2 - 29976651

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

M1 - 1701190

ER -